Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CanSino COVID-19 mRNA Vaccine (CS-2034)
NCT05373485Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Vaccine mRNA, Lipid-based Nanoparticles, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS-2034 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by CanSino Biologics Inc. Primary endpoint: The incidence of adverse reactions at 14 days. Started May 2022; status: completed.
02
Drugs
CS-2034
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05373485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373485.